Last reviewed · How we verify
NCT04092764
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN)
NA trial testing Electroacupuncture in Chemotherapy-induced Peripheral Neuropathy in 23 participants. Completed in 11 November 2021.
9 November 2021
Quick facts
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 23 |
| Start date | 23 January 2020 |
| Primary completion | 9 November 2021 |
| Estimated completion | 11 November 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Electroacupuncture
- NeuroMetrix
- Rydel-Seiffer tuning fork
Conditions studied
- Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Who can join
18 and older, any sex, with Chemotherapy-induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to determine the validity of a point-of-care nerve conduction device (NeuroMetrix) and Rydel-Seiffer tuning fork in assessing the level of peripheral neuropathy in patients with chemotherapy-induced peripheral neuropathy (CIPN). Chemotherapy-induced peripheral neuropathy (CIPN) is a common, persistent toxicity among patients who receive chemotherapy. It is characterized by a variety of sensory and motor symptoms such as numbness, tingling, reduced sense of touch, reduced proprioception (awareness of your limb and body position in space), pain, weakness, balance disturbances, and deficits in motor skills.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy.
Tsai CH, Lin YH, Li YS, Ho TL, et al · · 2021 · cited 12× · PMID 34502166 · DOI 10.3390/ijms22179257
Verify or expand the search:
- PubMed search for NCT04092764
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Electroacupuncture
Trials testing the same drug.
- NCT07530042 — Efficacy of Electroacupuncture Combined With Auricular Acupressure for Chronic Low Back Pain. · NA · not yet recruiting
- NCT07509294 — Effect Of Electroacupuncture With Local Anesthesia On Pain And Stress During Impacted Lower Third Molar Surgery · NA · not yet recruiting
- NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
- NCT07487532 — Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation · NA · not yet recruiting
- NCT07489625 — Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain · EARLY_PHASE1 · not yet recruiting
Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy
Currently open trials in the same condition.
- NCT07177820 — VGAIT for Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
- NCT07072468 — Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) · Phase 2 · recruiting
- NCT06389721 — Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy · recruiting
- NCT06405542 — Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) · Phase 1 · active not recruiting
- NCT06162403 — Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longi · NA · recruiting
Other H. Lee Moffitt Cancer Center and Research Institute trials
Trials by the same sponsor.
- NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
- NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
- NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
- NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
- NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04092764 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
- Last refreshed: 7 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04092764.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing